Compare ELAN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELAN | AXSM |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.0B |
| IPO Year | 2018 | 2015 |
| Metric | ELAN | AXSM |
|---|---|---|
| Price | $21.69 | $236.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $27.89 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 6.2M | 811.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $4,715,000,000.00 | N/A |
| Revenue This Year | $8.21 | $57.24 |
| Revenue Next Year | $5.31 | $55.88 |
| P/E Ratio | $192.45 | ★ N/A |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $12.90 | $96.09 |
| 52 Week High | $27.72 | $235.92 |
| Indicator | ELAN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 73.42 |
| Support Level | $21.22 | $179.00 |
| Resistance Level | $22.81 | N/A |
| Average True Range (ATR) | 1.37 | 7.06 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 35.05 | 95.81 |
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.